Genetic susceptibility to the development and progression of breast cancer associated with polymorphism of cell cycle and ubiquitin ligase genes

Carcinogenesis

Volumn 30, Issue 9, 2009, Pages 1562-1570

  Yu, Jyh Cherng ^a   Ding, Shian Ling ^b   Chang, Chih Hao ^c   Kuo, Shu Hsin ^d,e   Chen, Shou Tung ^f   Hsu, Giu Cheng ^a   Hsu, Huan Ming ^a   Hou, Ming Feng ^g   Jung, Lin Yi ^e   Cheng, Chun Wen ^h   Wu, Pei Ei ^d,e   Shen, Chen Yang ^d,e,i  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b Kang Ning Junior College of Medical Care and Management   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d ACADEMIA SINICA   (Taiwan)

^e INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN E; PROTEIN CDC4; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN;

ADULT; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL CYCLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FULL TERM PREGNANCY; GENE IDENTIFICATION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREGNANCY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BREAST TUMOR; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN E; DISEASE PROGRESSION; F-BOX PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; S-PHASE KINASE-ASSOCIATED PROTEINS; UBIQUITIN-PROTEIN LIGASES;

EID: 70249116108     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp173     Document Type: Article

References (39)

1. Sherr,C.J. et al. (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev., 18, 2699-2711.
2. Malumbres,M. et al. (2009) Cell cycle, CDKs and cancer: A changing paradigm. Nat. Rev. Cancer, 9, 153-166.
3. Nakayama,K.I. et al. (2006) Ubiquitin ligases: Cell-cycle control and cancer. Nat. Rev. Cancer, 6, 369-381.
4. Frescas,D. et al. (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the scales of cancer. Nat. Rev. Cancer, 8, 438-449.
5. Keyomarsi,K. et al. (2002) Cyclin E and survival in patients with breast cancer. N. Engl. J. Med., 347, 1566-1575.
6. Chu,I.M. et al. (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer, 8, 253-267.
7. Harris,L. et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 25, 5287-5312.
8. Carrano,A.C. et al. (1999) SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat. Cell Biol., 1, 193-199.
9. Strohmaier,H. et al. (2001) Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature, 413, 316-322.
10. Welcker,M. et al. (2008) FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer, 8, 83-93.
11. Fu,Y.P. et al. (2003) Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: A multigenic study on cancer susceptibility. Cancer Res., 63, 2440-2446.
12. Chou,W.C. et al. (2008) Chk2-dependent phosphorylation of XRCC1 in the DNA damage response promotes base excision repair. EMBO J., 27, 3140-3150.
13. Cheng,T.C. et al. (2005) Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: A multigenic study on cancer susceptibility. Int. J. Cancer, 113 345-353.
14. Russo,J. et al. (1982) Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res. Treat., 2 5-73.
15. Kelsey,J.L. et al. (1993) Reproductive factors and breast cancer. Epidemiol. Rev., 15, 36-47.
16. Sherr,C.J. et al. (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9, 1149-1163.
17. Yang,P.S. et al. (1997) A case-control study of breast cancer in Taiwana low-incidence area. Br. J. Cancer, 75, 752-756.
18. Lo,Y.L. et al. (1998) Allelic loss of the BRCA1 and BRCA2 genes and other regions on 17q and 13q in breast cancer among women from Taiwan (area of low incidence but early onset). Int. J. Cancer, 79, 580-587.
19. Huang,C.S. et al. (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: A multigenic study on cancer susceptibility. Cancer Res. 59, 4870-4875.
20. Shen,C.Y. et al. (2000) Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: An implication for mutator phenotype and breast cancer pathogenesis. Cancer Res., 60, 3884-3892.
21. Lung,J.C. et al. (2002) Aberrant expression of cell-cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability. Genes Chromosomes Cancer, 34, 276-284.
22. Huang,C.S. et al. (1999) Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in postmenopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int. J. Cancer, 82, 175-179.
23. Yang,H.C. et al. (2006) A comparison of major histocompatibility complex SNPs in Han Chinese residing in Taiwan and Caucasians. J. Biomed. Sci., 13, 489-498.
24. Lo,Y.L. et al. (2007) Breast cancer risk associated with genotypic polymorphism of the mitotic checkpoint genes: A multigenic study on cancer susceptibility. Carcinogenesis, 28, 1079-1086.
25. Ding,S.L. et al. (2009) Genetic variants of BLM interact with RAD51 to increase breast cancer susceptibility. Carcinogenesis, 30, 43-49.
26. International HapMap Consortium. et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851-861.
27. Ohnishi,Y. et al. (2001) A high-throughput SNP typing system for genomewide association studies. J. Hum. Genet., 46, 471-477.
28. Excoffier,L. et al. (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol., 12, 921-927.
29. Botto,L.D. et al. (2001) Commentary: Facing the challenge of geneenvironment interaction: The two-by-four table and beyond. Am. J. Epidemiol., 153, 1016-1020.
30. Kaplan,E.L. et al. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53, 457-481.
31. Hunt,K.K. et al. (2005) Cyclin E as a prognostic and predictive marker in breast cancer. Semin. Cancer Biol., 15, 319-326.
32. Tetzlaff,M.T. et al. (2004) Defective cardiovascular development and elevated cyclin E and Notch proteins in mice lacking the Fbw7 F-box protein. Proc. Natl Acad. Sci. USA, 101, 3338-3345.
33. Onoyama,I. et al. (2007) Conditional inactivation of Fbxw7 impairs cellcycle exit during T cell differentiation and results in lymphomatogenesis. J. Exp. Med., 204, 2875-2888.
34. Mao,J.H. et al. (2004) Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature, 432, 775-779.
35. Rajagopalan,H. et al. (2004) Inactivation of hCDC4 can cause chromosomal instability. Nature, 428, 77-81.
36. Andrieu,N. et al. (2006) Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J. Natl Cancer Inst., 98, 535-544.
37. Russo,J. et al. (2001) Mammary gland architecture as a determining factor in the susceptibility of the human breast to cancer. Breast J. 7, 278-291.
38. Akhoondi,S. et al. (2007) FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res., 67, 9006-9012.
39. Ekholm-Reed,S. et al. (2004) Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res., 64, 795-800.